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BRIEF COMMUNICATION
Pooled Analysis of Bleeding, Major Adverse  
Cardiovascular Events, and All-Cause 
Mortality in Clinical Trials of  
Time-Constrained Dual-Antiplatelet Therapy 
After Percutaneous Coronary Intervention
John D. McClure , PhD; Jennifer C. Ramsay, MBChB; Colin Berry , MD, PhD
BACKGROUND: The net clinical benefit of dual antiplatelet therapy (DAPT) reflects the paradoxical effects of an increased risk of 
bleeding and a reduced risk of major adverse cardiovascular events. A time-constrained approach to DAPT has been recently 
investigated in 5 multicenter trials including GLOBAL LEADERS, STOPDAPT2 (Short and Optimal Duration of Dual Antiplatelet 
Therapy After Everolimus-Eluting Cobalt-Chromium Stent-2), SMART-CHOICE, TWILIGHT (Ticagrelor With Aspirin or Alone 
in High-Risk Patients After Coronary Intervention), and TICO (Ticagrelor Monotherapy After 3 Months in the Patients Treated 
With New Generation Sirolimus Stent for Acute Coronary Syndrome).
METHODS AND RESULTS: We undertook a pooled analysis of these trials to assess the overall associations between time-
constrained P2Y12 inhibitor monotherapy (aspirin-free regimen) for bleeding events, major adverse cardiovascular events, and 
all-cause mortality as compared to standard care with DAPT for at least 12 months post-percutaneous coronary intervention. 
We implemented a DerSimonian and Laird random effects meta-analysis using the metafor package in R. 32 361 randomized 
trial participants, including 16 898 (52.2%) who had a history of acute coronary syndrome, underwent percutaneous coro-
nary intervention, and had outcome data available. P2Y12 inhibitor monotherapy from 1 to 3 months was associated with 
a reduced risk for bleeding (hazard ratio [HR] 0.60; 95% CI, 0.45-0.81), including in the acute coronary syndrome group in 
which the magnitude of risk reduction was greatest (HR 0.50; 95% CI, 0.41-0.61). The estimates of the effect of P2Y12 inhibitor 
monotherapy on the HR were also favorable for major adverse cardiovascular events (0.88; 95% CI, 0.77-1.02) and all-cause 
mortality (0.85; 95% CI, 0.71-1.03).
CONCLUSIONS: Compared with DAPT for 12 months post-percutaneous coronary intervention, P2Y12 inhibitor monotherapy 
from 1 to 3 months substantially reduces the risk of major and fatal bleeding and, in addition, confers potentially protective 
effects, for major adverse cardiovascular events and all-cause mortality. Considering patient safety, the results support a 
strategy of DAPT for 1 to 3 months followed by aspirin-free P2Y12 inhibitor monotherapy.
Key Words: acute coronary syndrome ■ antiplatelet agent ■ dual antiplatelet therapy ■ meta-analysis ■ percutaneous coronary 
intervention
Aspirin is established as the first-choice antiplate-let medication for secondary prevention of ath-erothrombotic events in patients with coronary 
artery disease.1–3 Because aspirin leads to incom-
plete antiplatelet inhibition, additional, dual antiplatelet 
therapy (DAPT) with an inhibitor of the platelet P2Y12 
receptor is now evidence based.2,3 In patients with 
stable coronary artery disease or an acute coronary 
syndrome (ACS) who are undergoing percutaneous 
coronary intervention (PCI), DAPT for 12  months is 
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recommended in practice guidelines.4 After discontin-
uation of DAPT, the options for long-term secondary 
prevention of atherothrombotic events include mono-
therapy with either aspirin or a P2Y12 inhibitor agent.
The CAPRIE (Clopidogrel versus Aspirin in Patients 
at Risk of Ischaemic Events) trial showed that in 
19 185 patients with atherosclerotic disease, includ-
ing 11 630 with myocardial infarction as the qualifying 
event, compared with aspirin monotherapy (325  mg 
per day), clopidogrel monotherapy (75 mg per day) for 
1.91 years reduced the incidence of ischemic stroke, 
myocardial infarction, or vascular death by 8.7% (95% 
CI, 0.3–16.5; P=0.043).5 There was a treatment inter-
action by disease subgroup suggesting that the true 
benefit of clopidogrel was less certain in patients with 
myocardial infarction (7.4% [−5.2 to 18.6]). On the other 
hand, severe bleeding was more common with aspirin, 
notably severe gastrointestinal bleeding (2.66% versus 
1.99%; P<0.05). A meta-analysis of 9 randomized trials 
of P2Y12 inhibitor monotherapy or aspirin for second-
ary prevention involving 42 108 patients found a bor-
derline risk reduction conferred by P2Y12 inhibitor for 
myocardial infarction (odds ratio, 0.81; 95% CI, 0.66–
0.99) but no evidence of a between-group difference in 
the risks of bleeding or all-cause mortality.6 The ongo-
ing ADAPTABLE trial aims to clarify the optimal dose of 
aspirin (81 or 325 mg, daily) for secondary prevention.7 
To date, no trial has compared aspirin monotherapy 
versus P2Y12 inhibitor monotherapy after initial treat-
ment with dual-antiplatelet therapy for 1/3 months after 
myocardial infarction.
Antiplatelet therapy is associated with an increased 
risk of major and fatal bleeding. The net clinical benefit 
reflects the paradoxical effects of an increased risk of 
bleeding, a reduced risk of major adverse cardiovas-
cular events (MACE) secondary to atherothrombosis, 
and, potentially, favorable effects on all-cause mortal-
ity. The competing risks of these events vary over time 
and are greatest early after the initial PCI. Accordingly, 
a time-constrained approach to DAPT after PCI has 
now been investigated in 5 multicenter clinical trials,8–12 
including GLOBAL LEADERS,8 STOPDAPT-2 (Short 
and Optimal Duration of Dual Antiplatelet Therapy 
After Everolimus-Eluting Cobalt-Chromium Stent-
2),9 SMART-CHOICE,10 TWILIGHT (Ticagrelor With 
Aspirin or Alone in High-Risk Patients After Coronary 
Intervention),11 and TICO (Ticagrelor Monotherapy After 
3 Months in the Patients Treated With New Generation 
Sirolimus Stent for Acute Coronary Syndrome).12
The rationale for our study was to assess the re-
sults of these trials. They shared a common aim, that 
is, to determine after an initial period of treatment with 
DAPT, whether, as compared with DAPT therapy for 
12 months post-PCI (standard care), time-constrained 
treatment with P2Y12 inhibitor monotherapy from 1 to 
3 months post-PCI would be safe and effective with 
respect to bleeding and MACE.
The trials had, by design, similarities and differ-
ences. Considering the timing and duration of study 
therapy, SMART-CHOICE, STOPDAPT-2, TWILIGHT, 
and TICO involved a strategy of P2Y12 inhibitor mono-
therapy from 3 to 12 months. GLOBAL LEADERS and 
STOPDAPT-2 involved P2Y12 inhibitor monotherapy 
after 1 month of DAPT, and, unlike the other trials, the 
duration of P2Y12 inhibitor monotherapy in GLOBAL-
LEADERS was 23 months. The P2Y12 inhibitor med-
ication also varied between the trials. STOPDAPT-2 
involved clopidogrel monotherapy, SMART-CHOICE 
involved any P2Y12 inhibitor, and GLOBAL LEADERS, 
TWILIGHT, and TICO involved ticagrelor monotherapy.
The TWILIGHT and TICO trials had similar designs 
although there were some important differences. 
TWILIGHT enrolled 7119 patients (n=4614 [65%] with 
an ACS) in 187 sites across 11 countries. TICO enrolled 
3056 patients with an ACS in 38 centers in Korea. 
TWILIGHT involved a double-blind, placebo-controlled 
design whereas TICO involved an open-label design 
without a placebo. The definitions for major bleeds, for 
example, Bleeding Academic Research Consortium 
grades 3 or 5, were broadly similar across the trials.
Our objective was to assess the overall associations 
in these trials between time-constrained P2Y12 inhibitor 
monotherapy (aspirin-free regimen) for bleeding events, 
MACE, and all-cause mortality as compared to standard 
care with DAPT for up to at least 12 months post-PCI.
METHODS
We will make the data and methods used in the analy-
sis available to any researcher for the purposes of re-
producing the results and procedures.
We undertook a pooled analysis of the data from 
these trials8–12 using DerSimonian and Laird random 
effects meta-analysis in the metafor package in R.13 
The results of the GLOBAL LEADERS trial for post-
PCI participants (though not for ACS subgroup) are 
presented as relative risk ratios whereas hazard ratios 
(HRs) are reported in the other trials. The outcomes 
were primary bleeding outcomes (major and fatal 
bleeds), MACE, and all-cause mortality at 12 months. 
Sensitivity analyses without the GLOBAL LEADERS 
Nonstandard Abbreviations and Acronyms
ACS acute coronary syndrome
DAPT dual antiplatelet therapy
MACE major adverse cardiovascular events
PCI percutaneous coronary intervention
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trial, and with fixed effects meta-analysis, confirm 
consistent effects. The analysis followed the Preferred 
Reporting Items for Systematic Reviews and Meta-
Analyses guidelines (http://www.prism a-state ment.
org/). Ethical committee review was not required.
RESULTS
In total, 32 361 patients treated with PCI had out-
come data available from 5 randomized, controlled 
trials of time-constrained DAPT for 1 to 3  months 
post-PCI followed by P2Y12 inhibitor monother-
apy versus DAPT for 12 months or longer. The tri-
als (subjects) were GLOBAL-LEADERS (n=15 968), 
SMART-CHOICE (n=2993), STOPDAPT-2 (n=3045), 
TWILIGHT (n=7199), and TICO (n=3056). The major-
ity of these patients had undergone PCI following an 
ACS (n=16 898 [52.2%]).
The main results are shown in Figure. The P2Y12 
inhibitor monotherapy strategy was associated with 
a reduced risk for bleeding post-PCI (HR, 0.60; 95% 
CI, 0.45-0.81) (Figure—Panel A), including in the sub-
group of patients presenting with an ACS in whom the 
magnitude of risk reduction was greatest (HR 0.50; 
95% CI, 0.41-0.61) (Figure—Panel B). The effect was 
directionally consistent across the trials. P2Y12 inhibi-
tor monotherapy was also associated with reductions 
in the overall estimates of the hazard of MACE (0.88; 
95% CI, 0.77-1.02) (Figure—Panel C), including in the 
ACS subgroup (0.86; 0.72-1.03) (Figure—Panel D), and 
all-cause mortality (0.85; 0.71-1.03) (Figure—Panel 
E), including in the ACS subgroup (0.73; 0.51-1.03) 
(Figure—Panel F), although the upper limit of the CIs 
marginally exceeded unity.
DISCUSSION
The pooled results of our analysis indicate that a 
time-constrained strategy of P2Y12 inhibitor mono-
therapy from 1 to 3  months post-PCI substantially 
Figure. Forest plots for the pooled analyses of the primary bleeding outcomes, major adverse cardiovascular events (MACE), 
and all-cause mortality in the 32 361 patients (n=16 898 [52.2%] with a history of acute coronary syndrome [ACS]) enrolled 
in the GLOBAL LEADERS8 (n=15 968), STOPDAPT-29 (n=3045), SMART-CHOICE10 (n=2993), TWILIGHT11 (n=7199), and TICO12 
(n=3056) clinical trial populations (A through F).
The results are presented for all patients following percutaneous coronary intervention (PCI) and for the subgroup presenting with an 
ACS for major bleeding outcomes (A and B), MACE (C and D), and all-cause mortality (E and F), respectively. As well as the overall 
random effects meta-analysis hazard ratio (HR) and its 95% CI, fixed effects (FE) analysis results are provided in each of the plots. The 
random effects and fixed effects meta-analyses give identical results for most outcomes. Where they differed (in post-PCI participants 
for the primary bleeding outcome and MACE), the non-zero I2 indicates the strength of between-study heterogeneity (Cochran’s Q test 
of heterogeneity is also given). The random effects meta-analysis should be used in preference, although it should be noted that the 
differences are small and have no material effect on the conclusions of the study. STOPDAPT-2 indicates Short and Optimal Duration 
of Dual Antiplatelet Therapy After Everolimus-Eluting Cobalt-Chromium Stent-2; TICO, Ticagrelor Monotherapy After 3 Months in the 
Patients Treated With New Generation Sirolimus Stent for Acute Coronary Syndrome; TWILIGHT, Ticagrelor With Aspirin or Alone in 
High-Risk Patients After Coronary Intervention.
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reduces the risk of major bleeding. The effect is 
greatest in patients with ACS in whom the risk of 
bleeding is halved.
The purpose for prescribing DAPT is to reduce the 
risk of MACE. Therefore, antiplatelet monotherapy that 
is prescribed instead of DAPT within 12 months of re-
ceiving PCI might be expected to be associated with 
an increased the risk of MACE, especially in post-ACS 
patients. In fact, reassuringly, we observed a direction-
ally opposite effect. In our analysis, the effect estimates 
for MACE and all-cause mortality were less than unity 
consistent with a lowering of the risks with P2Y12 inhib-
itor monotherapy. Importantly, considering the worst-
case scenario for the CI, the increase in the HRs was 
very small. By contrast, the magnitudes of the reduc-
tions in the HRs for MACE and all-cause mortality that 
were associated with P2Y12 inhibitor monotherapy are 
substantially greater and consistent with meaningful 
protective effects. These results are relevant to patient 
safety. Compared with DAPT for 12 months post-PCI, 
P2Y12 inhibitor monotherapy from 1 to 3 months post-
PCI halves the risk of major bleeding and may reduce 
the risks of MACE and death.
In clinical practice, discontinuation of antiplate-
let therapy in patients who are bleeding may lead 
to MACE, including spontaneous myocardial in-
farction and stent thrombosis. We have found that 
prolongation of DAPT to 12 months substantially in-
creases the risk of bleeding. Therefore, the clinical 
scenario that we describe may be less likely in pa-
tients receiving time-constrained, short-term DAPT 
for 1 to 3  months, which may be one explanation 
for the favorable safety signal for MACE as well as 
for bleeding. Bleeding and MACE are highly unde-
sirabe events. Considering the net clinical benefit 
of antiplatelet therapy, bleeding has a very strong 
association with persisting morbidity and mortality 
and elderly patients are particularly at risk.2 In this 
regard, practice guidelines recommend a focus on 
individualized risk (low versus high bleeding risk).2 
Accordingly, prevention of bleeding should be a pri-
mary consideration when prescribing the duration of 
DAPT in PCI and ACS patients.
The results of our analysis lend support to a strategy 
of discontinuing aspirin from 3  months post-PCI and 
continuing P2Y12 inhibitor monotherapy. Aspirin has 
been a long-established, first-line treatment for second-
ary prevention of coronary atherosclerosis and a shift 
to prescribing P2Y12 monotherapy is a new concept 
for clinicians. Recommendations from practice guide-
line committees will be important if clinical practice is 
to evolve in line with the evidence from these trials. The 
results are also relevant to the safety of participants in 
ongoing clinical trials comparing DAPT regimens.
Clinicians should still implement individualized ther-
apy decisions for their patients as would normally occur 
in daily practice. Currently, global prescribing practices 
for the type of P2Y12 inhibitor are influenced by several 
factors including access, absolute cost, clinical effec-
tiveness, and practice guidelines.
Limitations
The risks and benefits of aspirin monotherapy versus 
P2Y12 inhibitor monotherapy from 1/3 to 12  months 
following an ACS and/or PCI are not well established. 
In the future, a large clinical trial will be needed to ad-
dress this evidence gap.
CONCLUSIONS
P2Y12 inhibitor monotherapy from 1 to 3 months post-
PCI substantially reduces the risk of bleeding without 
an increase in MACE; rather, reductions in the risks of 
MACE and all-cause mortality are evident. There is no 
evidence of benefit with prolonged DAPT and clear 
signals harm. Our findings are highly relevant to the 
safety of patients prescribed DAPT, especially after 
an ACS. The results support a strategy of discontinu-
ing aspirin from 3  months post-PCI and continuing 
with “aspirin free” P2Y12 inhibitor monotherapy in the 
longer term.
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